Oct. 15, 2026 · show notes

Link

EPISODE

COMMUNITY

EMBED

EDIT

ABOUT THIS EPISODE

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)

CME information and select publications

Science

Medicine

English

United States

Use API to fetch this episode in JSON

SHOW NOTES 🔗

00:00:00Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL)

00:04:10Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring

00:10:05Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL

00:15:22Pirtobrutinib as first-line therapy for CLL and long-term safety data

TRANSCRIPT 🔗

Are you the producer of this podcast? Add a podcast transcript

Need Audio-to-Text? Transcribe with Listen411 in Just 60 Seconds

SEARCH PAST EPISODES

Search past episodes of Hematologic Oncology Update.

Embed this search bar to your website

OTHER EPISODES IN THIS PODCAST

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4

Sept. 7, 2026

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation a…

00:30:54

SAVE

CLIP

$Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program$

Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program

Sept. 2, 2026

Featuring perspectives from Dr William G Wierda, including the following topics: Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00) Sequencing Road Map (12:39) Key Datasets — Pirtobrutinib (21:08) Investigator Survey (34:09) Chimeric Antigen Receptor T-Cell T…

00:58:40

SAVE

CLIP

Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov

Sept. 23, 2026

Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives…

00:49:41

SAVE

CLIP

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

Sept. 6, 2026

Featuring perspectives from Prof John Seymour, including the following topics: Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00) Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21) First-line treatment with sonrotocl…

00:22:58

SAVE

CLIP

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus

Sept. 12, 2026

Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), …

00:59:49

SAVE

CLIP

Disclaimer: The podcast and artwork embedded on this page are from Dr. Neil Love, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.